ABSTRACT
A retrospective analysis of the database from A Coronary Disease Trial Investigating Outcome with Nifedipine (ACTION) evaluated the effectiveness of nifedipine gastrointestinal therapeutic system (GITS) (i) in combination with renin angiotensin system (RAS) blockers and (ii) in patients with isolated systolic hypertension (ISH). Analysed on an intention-to-treat basis, treatment groups were compared by the log-rank test without adjustment for covariates and hazard ratios with 95% CIs were obtained using Cox proportional hazards models. Of 7665 randomized patients, 1732 patients were receiving RAS blockade at baseline, the addition of nifedipine GITS significantly reduced any cardiovascular (CV) event (-20%; P<0.05), the composite of death, any CV event and revascularization (-16%; P<0.05) and coronary angiography (-22%; P<0.01). These benefits were achieved with relatively small differences in systolic (3.2 mm Hg) and diastolic blood pressure (BP) (2.3 mm Hg). In 2303 patients (30.0%) who had ISH at baseline (1145 nifedipine GITS and 1158 placebo), nifedipine significantly reduced the primary efficacy end point (-18%; P<0.03), any CV event (-22%; P<0.01) and new heart failure (-40%; P<0.01). The benefits were associated with between-group differences in achieved BP of 4.7 and 3.3 mm Hg for systolic and diastolic BP, respectively. In summary, the lowest CV event rates were seen in those receiving (i) the combination of RAS blockade and nifedipine GITS and (ii) in those specifically treated for ISH.
Subject(s)
Angina Pectoris/drug therapy , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Nifedipine/therapeutic use , Vasodilator Agents/therapeutic use , Aged , Angina Pectoris/physiopathology , Angiotensin Receptor Antagonists/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Blood Pressure/drug effects , Blood Pressure/physiology , Cardiovascular Diseases/epidemiology , Drug Therapy, Combination , Female , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Male , Middle Aged , Nifedipine/pharmacology , Prevalence , Proportional Hazards Models , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/physiology , Retrospective Studies , Vasodilator Agents/pharmacologyABSTRACT
BACKGROUND: Immunosuppressive treatment with cyclosporin A (CsA) improves the survival of renal allografts, but is associated with renal vasoconstriction and hypertension. Previous reports suggest that the calcium-channel blockers nifedipine and amlodipine may improve graft function in CsA-treated patients. We have compared the effects of amlodipine (5-10 mg once daily) and nifedipine retard (10-40 mg twice daily) on renal function and blood pressure in renal transplant recipients treated with CsA. METHODS: This was a multicentre, two-way, crossover study in 27 evaluable hypertensive patients with renal insufficiency following renal transplantation, who were maintained on a stable dose of CsA. Patients received either amlodipine (5-10 mg once daily) or nifedipine retard (10-40 mg twice daily) for 8 weeks, and were then crossed over to the other treatment for a further 8 weeks. RESULTS: Trends were seen during amlodipine treatment towards larger improvements, in serum creatinine (by 8% of baseline on amlodipine vs 4% on nifedipine), lithium clearance (13% vs 2%), and glomerular filtration rate 11% vs 7%). Effective renal plasma flow was increased by 11% of baseline on nifedipine vs 9% on amlodipine. There were no significant differences between treatments. Amlodipine and nifedipine lowered systolic blood pressure to a similar extent (21 mmHg vs 15 mmHg respectively, P=0.25), but amlodipine was more effective than nifedipine in lowering diastolic blood pressure (13 mmHg vs 8 mmHg, P=0.006). Both treatments were well tolerated. CONCLUSION: Once-daily amlodipine is at least as effective as twice-daily nifedipine retard in controlling blood pressure and does not adversely affect graft function in hypertensive renal allograft recipients.
Subject(s)
Amlodipine/therapeutic use , Calcium Channel Blockers/therapeutic use , Hypertension/drug therapy , Kidney Transplantation , Kidney/drug effects , Nifedipine/therapeutic use , Renal Plasma Flow/drug effects , Adolescent , Adult , Aged , Blood Pressure/drug effects , Cross-Over Studies , Cyclosporine/adverse effects , Cyclosporine/therapeutic use , Female , Follow-Up Studies , Glomerular Filtration Rate/drug effects , Graft Rejection/physiopathology , Graft Rejection/prevention & control , Humans , Hypertension/chemically induced , Kidney/physiopathology , Kidney Transplantation/physiology , Male , Middle Aged , Single-Blind MethodABSTRACT
There is evidence that the renin-angiotensin system may be involved in the metabolic as well as the cardiovascular features of diabetes and that pressor doses of angiotensin II (ANG II) increase insulin sensitivity in parallel with blood pressure (BP) in healthy subjects, but the effects of ANG II on insulin sensitivity have not been previously reported in patients with non-insulin-dependent diabetes mellitus (NIDDM). In a randomized, double-blind, placebo-controlled, crossover study, 11 patients with NIDDM attended 3 study days to evaluate the effects of a 3-h infusion of subpressor and pressor doses of ANG II on whole body insulin sensitivity using the euglycemic hyperinsulinemic clamp. BP and heart rate were recorded, and blood samples were collected for serum insulin, C-peptide, potassium, catecholamines, plasma renin activity, and plasma ANG II concentrations. Plasma levels of ANG II (means +/- SD) were 9 +/- 4, 29 +/- 9, and 168 +/- 47 pmol/ml after placebo, low dose infusion, and high dose infusion, respectively. The higher dose of ANG II was associated with significant increases in BP (e.g., 18 mmHg systolic BP at 150 min) and plasma aldosterone. Whole body insulin sensitivity was 23.8 +/- 12.7 mumol glucose.kg-1.min-1 after placebo and 30.6 +/- 12.7 and 27.2 +/- 13.3 following low and high dose ANG II infusions, respectively (P < 0.05, analysis of variance). In summary, acute infusion of ANG II, with or without an increase in BP, increases insulin sensitivity in normotensive patients with NIDDM.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Angiotensin II/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Insulin/pharmacology , Adult , Aged , Aldosterone/blood , Angiotensin II/blood , Angiotensin II/therapeutic use , Blood Pressure , C-Peptide/blood , Cardiac Output , Cross-Over Studies , Diabetes Mellitus, Type 2/physiopathology , Double-Blind Method , Female , Heart Rate , Humans , Insulin/blood , Male , Middle Aged , Placebos , Potassium/blood , Triglycerides/bloodABSTRACT
The predictability of the long term antihypertensive response to nifedipine in individual patients has been assessed by an analysis based upon the concentration-effect parameters defined following the first dose administration of 20 mg nifedipine (Retard). The predicted and measured reductions in blood pressure during steady state nifedipine treatment were compared for the trough and peak responses and there was reasonable agreement for the group of patients as a whole. However, when the measured and predicted blood pressure profiles were compared for each individual patient there was close agreement for the majority of patients but there were significant discrepancies in a few cases. Further analysis of the steady state concentrations in these cases revealed that there was no change in their responsiveness to nifedipine and that discrepancies were directly attributable to inappropriate compliance with the drug regimen. The analysis was further extended to simulate the blood pressure responses to alternative fixed dosage regimens. Assessment of these simulations suggests that blood pressure control with nifedipine Retard is significantly improved by three times daily drug administration.
Subject(s)
Hypertension/drug therapy , Nifedipine/therapeutic use , Blood Pressure/drug effects , Computer Simulation , Delayed-Action Preparations , Dose-Response Relationship, Drug , Female , Humans , Hypertension/blood , Male , Nifedipine/administration & dosage , Nifedipine/blood , Nifedipine/pharmacokinetics , Single-Blind MethodABSTRACT
It is now apparent that the incidence of inadequate compliance is greater than had previously been recognised. The pattern of poor compliance is generally characterised by underdosing rather than overdosing and will usually involve interruptions in therapy of several days. There are many potentially important consequences of this, but therapeutically the most important is associated with the period without drug action. Establishing, for a range of antihypertensive agents, that there is a clear relationship between the circulating drug concentration and blood pressure-lowering effect it is possible to demonstrate that the pharmacodynamic characteristics of a drug will be well correlated with its pharmacokinetics. Thus, compared with other agents, amlodipine with its relatively smooth concentration-time profile and long elimination half-life will be superior in maintaining blood pressure control both with perfect compliance and when dosage regimens are perturbed due to missed drug doses.
Subject(s)
Hypertension/drug therapy , Patient Compliance , Drug Administration Schedule , Enalapril/therapeutic use , Humans , Nifedipine/therapeutic useSubject(s)
Amlodipine/administration & dosage , Blood Pressure/drug effects , Nifedipine/administration & dosage , Adult , Angiotensin II/pharmacology , Blood Pressure/physiology , Delayed-Action Preparations , Digestive System/drug effects , Double-Blind Method , Humans , Male , Norepinephrine/pharmacology , Time FactorsABSTRACT
Pharmacodynamic and pharmacokinetic interactions have been reported when an alpha 1-antagonist is combined with a calcium antagonist. We evaluated the clinical usefulness of the combination of nifedipine (20 mg twice daily, b.i.d.) and doxazosin (2 mg once daily, o.d.) in hypertensive patients in whom blood pressure (BP) control was suboptimal after doxazosin (group A) or nifedipine (group B) as monotherapy and investigated the underlying kinetic and dynamic interactions, including changes in vascular responsiveness to i.v. infusions of angiotensin II (ANGII) and phenylephrine (PE). The combination was well tolerated and associated with further significant reductions in BP. After 4 weeks of combined therapy, average supine BP over 8 h was 122/77 in group A and 137/80 in group B as compared with 140/86 and 150/88 mm Hg, respectively, during monotherapy + placebo. The combination attenuated both phenylephrine and ANG-induced pressor responses: e.g., the mean PD15 values (dose of agonist required to increase systolic BP by 15 mm Hg) for group A at 1.5-3 h were 3.5 micrograms/kg/min for PE and 7.5 ng/kg/min for ANGII as compared with 2.9 and 2.3, respectively, during treatment with doxazosin and placebo. There was no evidence of a significant kinetic interaction between the two drugs and, in particular, addition of nifedipine had no effect on the steady-state kinetics of doxazosin. In conclusion, doxazosin and nifedipine are an effective antihypertensive combination in patients who require treatment with more than one drug.
Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Nifedipine/therapeutic use , Prazosin/analogs & derivatives , Aged , Analysis of Variance , Angiotensin II/pharmacology , Blood Pressure/drug effects , Doxazosin , Drug Therapy, Combination , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Nifedipine/administration & dosage , Nifedipine/pharmacokinetics , Phenylephrine/pharmacology , Prazosin/administration & dosage , Prazosin/pharmacokinetics , Prazosin/therapeutic useABSTRACT
Thirty-seven essential hypertensives received placebo for 3 weeks followed by nifedipine retard (n = 14) or enalapril (n = 13) or doxazosin (n = 10) as monotherapy for 6 weeks and attended study days to evaluate the effects of placebo, first dose, and chronic (1-6 weeks) treatment. On each study day, pressor responses to i.v. infusions of phenylephrine (PE) and angiotensin II (AII) were measured 1.5-3 h after drug administration and the derived PD20 values (dose required to increase mean blood pressure by 20 mm Hg) compared. Each treatment produced comparable reductions in BP. Nifedipine significantly attenuated the pressor responses to AII and PE: for AII, the mean PD20 (ng/kg/min) increased from 8.2 (placebo) to 9.9 (first dose), 13.9 (1 week), and 17.4 (6 weeks). Pressor responsiveness to both AII and PE was unchanged following enalapril: for PE, the mean PD20 (micrograms/kg/min) was 2.1 (placebo), 1.5 (first dose), and 1.5 (6 weeks). Doxazosin produced rightward shifts of the PE pressor dose-response curves but had no effect on responses to AII. The relationship between the simultaneous BP and HR changes during the infusion of PE was used as an index of cardiac baroreflex activity. In contrast to enalapril and doxazosin, which had no effect, nifedipine reduced the slope of the HR/BP relationship from -0.62 (placebo) to -0.38 (first dose) and -0.31 beats/min/mm Hg (6 weeks). For comparable reductions in BP, doxazosin only affects adrenergic mechanisms whereas nifedipine affects both adrenergic and non-adrenergically mediated vasoconstriction. The ACE inhibitor enalapril had no effect on pressor responses to AII and PE.
Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Hypertension/drug therapy , Adult , Aged , Aldosterone/blood , Angiotensin II/blood , Angiotensin II/therapeutic use , Catecholamines/blood , Doxazosin , Enalapril/blood , Enalapril/therapeutic use , Female , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Male , Middle Aged , Nifedipine/blood , Nifedipine/therapeutic use , Peptidyl-Dipeptidase A/blood , Phenylephrine/blood , Phenylephrine/therapeutic use , Prazosin/analogs & derivatives , Prazosin/blood , Prazosin/therapeutic use , Reflex/drug effects , Regional Blood Flow/drug effects , Renin/bloodABSTRACT
We evaluated the usefulness of an integrated concentration-effect modelling technique in predicting the long-term response to antihypertensive therapy with enalapril and nifedipine. Two groups of essential hypertensives were given monotherapy with 20 mg nifedipine twice a day (n = 14) or 20 mg enalapril once a day (n = 13), and were studied following the administration of the drugs and after at least 6 weeks' treatment. For both drugs the predicted responses (predose and 4 h postdose) were in close agreement with the observed responses. With enalapril the observed and predicted profiles over a 12-h study period were well correlated in all subjects. In contrast, with nifedipine, although there was generally good agreement, the model over-predicted the profile of response in one patient and under-predicted the profile in one patient. Thus, there is evidence that application of concentration-effect analysis is useful in predicting the steady-state antihypertensive effect from the first dose-response to the drug.
Subject(s)
Enalapril/therapeutic use , Hypertension/drug therapy , Nifedipine/therapeutic use , Blood Pressure/drug effects , Drug Evaluation , Enalapril/blood , Humans , Hypertension/blood , Hypertension/physiopathology , Models, Biological , Nifedipine/blood , Prognosis , Time FactorsABSTRACT
Pharmacokinetic and pharmacodynamic variability account for the large interindividual differences in the antihypertensive response to treatment with a calcium antagonist. Using an integrated kinetic-dynamic model, the acute and chronic (4-6 weeks) responses to nifedipine (n = 14) and verapamil (n = 14) were characterized for individual hypertensive patients in terms of fall in blood pressure per unit drug concentration. The responsiveness to nifedipine, as the mean of the group, was -0.48 mm Hg/ng/ml following the first dose and -0.49 mm Hg/ng/ml after chronic dosing. The corresponding values for verapamil were -0.13 and -0.12 mm Hg/ng/ml, respectively. For nifedipine and verapamil, the responsiveness to the first dose was significantly correlated both with the height of the pretreatment blood pressure (p less than 0.001) and the responsiveness after 4-6 weeks of treatment (p less than 0.001). Parameters derived from an individual approach to concentration-effect analysis are useful for evaluating the determinants of response to calcium antagonists and form a potential basis for optimizing drug therapy in individual patients.
Subject(s)
Calcium Channel Blockers/therapeutic use , Hypertension/drug therapy , Adult , Aged , Blood Pressure/drug effects , Calcium Channel Blockers/pharmacokinetics , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Nifedipine/pharmacokinetics , Nifedipine/therapeutic use , Sympathetic Nervous System/drug effects , Verapamil/pharmacokinetics , Verapamil/therapeutic useABSTRACT
1 Herbal preparations containing atropine-like alkaloids are marketed as proprietory asthma remedies, typically in the form of cigarettes. 2 This randomised, cross-over study compares in six healthy volunteers the pharmacological effects caused by smoking a standard, medium tar, tobacco cigarette or a herbal cigarette. 3 Smoking a herbal cigarette is associated with a significant fall in heart rate consistent with the systemic response to atropine-like alkaloids and a significant increase in peak expiratory flow rate consistent with the bronchodilator effect of reduced cholinergic activity. 4 Smoking a herbal cigarette seems analogous to the inhalation of ipratropium by aerosol for a local bronchodilator effect.
Subject(s)
Asthma/drug therapy , Phytotherapy , Adult , Female , Heart Rate/drug effects , Hemodynamics/drug effects , Humans , Male , Peak Expiratory Flow Rate , Pupil/drug effects , Salivation/drug effects , SmokingABSTRACT
Whole body calcium, phosphorus and nitrogen have been measured by in vivo neutron activation analysis in patients with chronic renal failure, including 9 with dialysis encephalopathy. Aluminium was also activated by this procedure, but to the same radioactive product as that from phosphorus: its presence was therefore detected as an increase in the apparent total body phosphorus above that expected for a person with the same calcium content. Patients with dialysis encephalopathy had slightly more apparent phosphorus than others with chronic renal failure, although the difference was not statistically significant. This difference corresponded to an excess of aluminium not greater than 3.3 g(95% confidence limit) which places an upper limit on excess aluminium accumulation in this condition.